Figure 2.

Scatter graph showing the relationship between treatment-free interval or initial-to-second period duration and phospho-S6 ribosomal protein (pS6) immunostaining. (A) HT group: Patients who received HT after diagnosis of the initial tumour; the treatment-free interval of pS6 immunohistochemistry-negative patients was 91.5±73.6 months, that of pS6-positive patients was 19.4±15.8 months, and that of pS6-strongly positive patients was 6.3±12.5 months. There was a rank correlation between the treatment-free interval and pS6 immunostaining (P<0.0003) according to Spearman correlation analysis (ρ=−0.5355). (B) No HT group: Patients who did not receive HT after diagnosis of the initial tumour; the initial-to-second period duration of pS6 immunohistochemistry-negative patients was 88.4±67.2 months, that of pS6-positive patients was 208±0 months, and that of pS6-strongly positive patients was 62.0±42.2 months. There was no rank correlation between the initial-to-second period duration and pS6 immunostaining (P=0.756) according to Spearman correlation analysis (ρ=−0.0814). HT, hormone therapy.